O	0	3	The
O	4	10	Effect
O	11	13	of
O	14	28	Intraoperative
O	29	37	Systemic
B-intervention	38	47	Lidocaine
O	48	50	on
B-condition	51	64	Postoperative
I-condition	65	75	Persistent
I-condition	76	80	Pain
O	81	86	Using
O	87	97	Initiative
O	98	100	on
O	101	108	Methods
O	108	109	,
O	110	121	Measurement
O	121	122	,
O	123	126	and
O	127	131	Pain
O	132	142	Assessment
O	143	145	in
O	146	154	Clinical
O	155	161	Trials
O	162	170	Criteria
O	171	181	Assessment
O	182	191	Following
O	192	198	Breast
O	199	205	Cancer
O	206	213	Surgery
O	213	214	:
O	215	216	A
O	217	227	Randomized
O	227	228	,
O	229	235	Double
O	235	236	-
O	236	241	Blind
O	241	242	,
O	243	250	Placebo
O	250	251	-
O	251	261	Controlled
O	262	267	Trial
O	267	268	.

O	269	271	To
O	272	279	compare
O	280	283	the
O	284	293	incidence
O	294	296	in
O	297	309	postsurgical
O	310	320	persistent
O	321	325	pain
O	326	335	following
O	336	342	breast
O	343	349	cancer
O	350	357	surgery
O	358	360	in
O	361	366	women
O	367	376	receiving
O	377	388	intravenous
O	389	398	lidocaine
O	399	407	compared
O	408	410	to
O	411	417	saline
O	418	423	using
O	424	433	validated
O	434	438	pain
O	439	450	instruments
O	451	453	in
O	454	464	accordance
O	465	469	with
O	470	473	the
O	474	484	Initiative
O	485	487	on
O	488	495	Methods
O	495	496	,
O	497	508	Measurement
O	508	509	,
O	510	513	and
O	514	518	Pain
O	519	529	Assessment
O	530	532	in
O	533	541	Clinical
O	542	548	Trials
O	549	550	(
O	550	557	IMMPACT
O	557	558	)
O	559	574	recommendations
O	574	575	.

O	576	579	The
O	580	585	study
O	586	589	was
O	590	591	a
O	592	602	randomized
O	602	603	,
O	604	610	double
O	610	611	-
O	611	618	blinded
O	618	619	,
O	620	627	placebo
O	627	628	-
O	628	638	controlled
O	638	639	,
O	640	648	clinical
O	649	654	trial
O	654	655	.

O	656	664	Subjects
O	665	669	were
O	670	680	randomized
O	681	685	into
O	686	691	Group
O	692	693	1
O	694	695	(
O	695	696	1
O	696	697	.
O	697	698	5
O	699	701	mg
O	701	702	/
O	702	704	kg
O	705	710	bolus
O	711	713	of
O	714	725	intravenous
O	726	735	lidocaine
O	736	744	followed
O	745	747	by
O	748	749	a
O	750	751	2
O	752	754	mg
O	754	755	/
O	755	757	kg
O	757	758	/
O	758	762	hour
O	763	771	infusion
O	771	772	)
O	773	775	or
O	776	781	Group
O	782	783	2
O	784	785	(
B-control	785	791	normal
I-control	792	798	saline
O	799	801	at
O	802	805	the
O	806	810	same
O	811	816	bolus
O	817	820	and
O	821	829	infusion
O	830	834	rate
O	834	835	)
O	835	836	.

O	837	845	Patients
O	846	850	were
O	851	860	evaluated
O	861	863	at
O	864	865	3
O	866	869	and
O	870	871	6
O	872	878	months
O	879	882	for
O	883	886	the
O	887	895	presence
O	896	898	of
O	899	906	chronic
O	907	917	persistent
O	918	930	postsurgical
O	931	935	pain
O	935	936	.

B-total-participants	937	940	One
I-total-participants	941	948	hundred
I-total-participants	949	954	forty
I-total-participants	954	955	-
I-total-participants	955	960	eight
O	961	969	patients
O	970	974	were
O	975	983	included
O	984	986	in
O	987	990	the
O	991	996	study
O	997	1005	analysis
O	1005	1006	.

O	1007	1012	There
O	1013	1017	were
O	1018	1020	no
O	1021	1032	differences
O	1033	1035	in
B-outcome	1036	1043	quality
I-outcome	1044	1046	of
I-outcome	1047	1055	recovery
O	1055	1056	,
B-outcome	1057	1061	pain
I-outcome	1062	1068	burden
O	1068	1069	,
O	1070	1072	or
B-outcome	1073	1079	opioid
I-outcome	1080	1091	consumption
O	1092	1099	between
O	1100	1106	groups
O	1107	1109	at
O	1110	1112	24
O	1113	1118	hours
O	1118	1119	.

B-outcome	1120	1124	Pain
I-outcome	1125	1126	(
I-outcome	1126	1129	yes
I-outcome	1129	1130	/
I-outcome	1130	1132	no
I-outcome	1132	1133	)
I-outcome	1134	1136	at
I-outcome	1137	1138	6
I-outcome	1139	1145	months
O	1146	1156	attributed
O	1157	1159	to
O	1160	1167	surgery
O	1168	1171	was
O	1172	1180	reported
O	1181	1183	in
B-cv-bin-percent	1184	1186	29
I-cv-bin-percent	1186	1187	%
O	1188	1190	of
O	1191	1196	Group
O	1197	1198	2
O	1199	1201	vs
O	1201	1202	.
B-iv-bin-percent	1203	1205	13
I-iv-bin-percent	1205	1206	%
O	1207	1209	of
O	1210	1215	Group
O	1216	1217	1
O	1218	1226	patients
O	1227	1228	(
O	1228	1229	P
O	1230	1231	=
O	1232	1233	0
O	1233	1234	.
O	1234	1236	04
O	1236	1237	)
O	1237	1238	;
O	1239	1246	however
O	1246	1247	,
O	1248	1252	only
B-iv-bin-abs	1253	1254	3
O	1255	1263	subjects
O	1264	1265	(
B-iv-bin-percent	1265	1266	5
I-iv-bin-percent	1266	1267	%
O	1267	1268	)
O	1269	1271	in
O	1272	1277	Group
O	1278	1279	1
O	1280	1283	and
B-cv-bin-abs	1284	1285	2
O	1286	1294	subjects
O	1295	1296	(
B-cv-bin-percent	1296	1297	3
I-cv-bin-percent	1297	1298	%
O	1298	1299	)
O	1300	1302	in
O	1303	1308	Group
O	1309	1310	2
O	1311	1314	met
O	1315	1322	IMMPACT
O	1323	1331	criteria
O	1332	1335	for
B-outcome	1336	1346	persistent
I-outcome	1347	1360	postoperative
I-outcome	1361	1365	pain
O	1366	1367	(
O	1367	1368	P
O	1369	1370	=
O	1371	1372	0
O	1372	1373	.
O	1373	1375	99
O	1375	1376	)
O	1376	1377	.

O	1378	1391	Perioperative
O	1392	1400	infusion
O	1401	1403	of
O	1404	1413	lidocaine
O	1414	1417	has
O	1418	1422	been
O	1423	1431	reported
O	1432	1434	to
O	1435	1443	decrease
O	1444	1447	the
B-outcome	1448	1457	incidence
I-outcome	1458	1460	of
I-outcome	1461	1473	postsurgical
I-outcome	1474	1478	pain
O	1479	1481	at
O	1482	1483	3
O	1484	1487	and
O	1488	1489	6
O	1490	1496	months
O	1497	1506	following
O	1507	1517	mastectomy
O	1518	1523	using
O	1524	1535	dichotomous
O	1536	1537	(
O	1537	1540	yes
O	1540	1541	/
O	1541	1543	no
O	1543	1544	)
O	1545	1552	scoring
O	1552	1553	.

O	1554	1562	Although
O	1563	1574	intravenous
O	1575	1584	lidocaine
O	1585	1592	reduced
O	1593	1596	the
O	1597	1605	reported
B-outcome	1606	1615	incidence
I-outcome	1616	1618	of
I-outcome	1619	1623	pain
O	1624	1626	at
O	1627	1631	rest
O	1632	1634	at
O	1635	1636	6
O	1637	1643	months
O	1643	1644	,
B-outcome	1645	1649	pain
I-outcome	1650	1654	with
I-outcome	1655	1663	activity
O	1663	1664	,
B-outcome	1665	1669	pain
I-outcome	1670	1679	qualities
O	1679	1680	,
O	1681	1684	and
O	1685	1688	the
B-outcome	1689	1697	physical
I-outcome	1698	1700	or
I-outcome	1701	1710	emotional
I-outcome	1711	1717	impact
I-outcome	1718	1720	of
I-outcome	1721	1724	the
I-outcome	1725	1729	pain
O	1730	1734	were
O	1735	1745	unaffected
O	1745	1746	.

O	1747	1753	Future
O	1754	1761	studies
O	1762	1772	evaluating
O	1773	1785	postsurgical
O	1786	1796	persistent
O	1797	1801	pain
O	1802	1808	should
O	1809	1815	adhere
O	1816	1818	to
O	1819	1822	the
O	1823	1830	IMMPACT
O	1831	1846	recommendations
O	1847	1849	in
O	1850	1855	order
O	1856	1858	to
O	1859	1863	more
O	1864	1874	accurately
O	1875	1883	describe
O	1884	1887	the
O	1888	1894	effect
O	1895	1897	of
O	1898	1900	an
O	1901	1913	intervention
O	1914	1916	on
O	1917	1927	persistent
O	1928	1932	pain
O	1932	1933	.
